BioSpace News Archive

Exact Sciences Corp. announced late-breaking data from the pivotal BLUE-C trial showing the next-generation Cologuard® test met all study endpoints, demonstrating 94 percent sensitivity for colorectal cancer at 91% specificity, during the American College of Gastroenterology Annual Meeting 2023.

Adiso Therapeutics, Inc. announced positive topline data from its Phase 1b multiple ascending dose clinical trial evaluating ADS051 in patients with moderate-to-severe ulcerative colitis.

Revolution Medicines, Inc. announced promising anti-tumor and safety data for RMC-6236, its RASMULTI Inhibitor, in patients with previously treated non-small cell lung cancer and pancreatic ductal adenocarcinoma across several dose levels and KRASG12X genotypes, including common KRAS-mutant genotypes G12D and G12V.

The Janssen Pharmaceutical Companies of Johnson & Johnson announced results from the final analysis of the Phase 3 MAGNITUDE study.

Updated results from a subgroup analysis of a first-in-human phase 1 trial showed that raludotatug deruxtecan continues to demonstrate promising clinical activity in patients with heavily pretreated platinum-resistant advanced ovarian cancer.

Amgen announced data from the global Phase 3 CodeBreaK 300 trial evaluating two doses of LUMAKRAS® in combination with Vectibix®.

Updated results from the BEGONIA phase 1b/2 trial for the cohort of patients treated with datopotamab deruxtecan plus durvalumab showed that the combination demonstrated durable tumor responses and no new safety signals in patients with previously untreated advanced or metastatic triple negative breast cancer with six months additional follow-up from the previous data cut-off.

Jacobio Pharma is pleased to announce that the clinical data of glecirasib in combination with JAB-3312 was published in the form of a proffered paper presentation at the 2023 European Society for Medical Oncology Congress.

The Janssen Pharmaceutical Companies of Johnson & Johnson announced the first results from an open-label, multicenter Phase 1 study evaluating the safety and efficacy of TAR-210, an intravesical delivery system designed to provide sustained, local release of erdafitinib into the bladder in patients with non-muscle-invasive bladder cancer with select fibroblast growth factor receptor alterations.

Astellas Pharma Inc. and Seagen Inc. announced results from the Phase 3 EV-302 clinical trial for PADCEV® in combination with KEYTRUDA® versus chemotherapy.